Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AGEN1571 + botensilimab
- Development stage
- Unknown
- Lead developer
- Agenus
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AGEN1571 + botensilimab is an investigational combination therapy for advanced solid tumors, being developed by Agenus. AGEN1571 is a novel anti-ILT2 monoclonal antibody that modulates tumor-associated macrophages, T, NK, and NKT cells to promote anti-tumor immune activity, overcoming resistance to PD-1-directed therapies. Botensilimab (AGEN1181) is an Fc-enhanced anti-CTLA-4 monoclonal antibody engineered to stimulate both innate and adaptive immune responses by robustly engaging activating Fc receptors on key immune cells, thereby activating T cells, depleting tumor-infiltrating regulatory T cells, and priming the tumor microenvironment for effective antitumor immunity. The combination is evaluated primarily in advanced solid tumors, including refractory microsatellite-stable metastatic colorectal cancer, with agents targeting distinct immune checkpoints to enhance and broaden the response to immunotherapy[1][2][3].
- Other names
- AGEN1571 + botensilimab
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)LILRB1 (Leukocyte immunoglobulin-like receptor subfamily B member 1)
Beyond the preview
Go deeper on AGEN1571 + botensilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AGEN1571 + botensilimab.